Joana Antunes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joana Antunes has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Gustavo Almeida-Silva
Department of Dermatology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte , Lisbon
12 shared publications - Paulo Filipe
Serviço de Dermatologia, Unidade Local de Saúde Santa Maria (ULSSM), Hospital de Santa Maria, Lisboa, Portugal
9 shared publications - Filipe Monteiro
Dermatology Department. Unidade Local de Saúde Santa Maria. Lisboa. & University Clinic of Dermatology. Faculdade de Medicina. Universidade de Lisboa. Lisboa...
6 shared publications - Luís Soares-De-Almeida
Dermatology Department Unidade Local de Saúde Santa Maria Lisbon Portugal
6 shared publications - Inês Pereira Amaral
Hospital Santa Maria, Lisbon
5 shared publications - Inês Tribolet de Abreu
Unidade Local de Saúde Santa Maria
5 shared publications
Latest Publications
- 19 November 2026
- Published by Elsevier in The American Journal of Medicine
A 54-year-old woman with a painful photodistributed blistering eruption
- 19 November 2026
- Published by Elsevier in The American Journal of Medicine
A 54-year-old woman with a painful photodistributed blistering eruption
- 30 September 2026
- Published by Publicacoes Ciencia e Vida, Lda in Revista Portuguesa de Imunoalergologia
- Vol. 34 (3) , 165-167
Quando o jantar deixa marca: Um caso de dermatite flagelada induzida por cogumelos shiitake
- 30 September 2026
- Published by Publicacoes Ciencia e Vida, Lda in Revista Portuguesa de Imunoalergologia
- Vol. 34 (3) , 165-167
Quando o jantar deixa marca: Um caso de dermatite flagelada induzida por cogumelos shiitake
- Open Access
- 31 July 2026
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 16 (3) , 6663
Dermoscopy of Capillary Malformations in Capillary Malformation-Arteriovenous Malformation Syndrome Type 2
- 31 July 2026
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 16 (3) , 6663
Open AccessDermoscopy of Capillary Malformations in Capillary Malformation-Arteriovenous Malformation Syndrome Type 2
- Open Access
- 24 June 2026
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 39 (8) , 503-504
Cutaneous Polyarteritis Nodosa as the Inaugural Manifestation of Hairy Cell Leukemia
- 24 June 2026
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 39 (8) , 503-504
Open AccessCutaneous Polyarteritis Nodosa as the Inaugural Manifestation of Hairy Cell Leukemia
- Open Access
- 11 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4525
Segmental PASI Evaluation Reveals Reduced PUVA Responsiveness of Lower-Limb Psoriasis in Patients with Internal Organ Malignancy
Background/Objectives: The management of moderate-to-severe psoriasis in patients with a recent history of internal malignancy is a clinical challenge, as systemic immunosuppressive therapies are often avoided because of concerns about cancer recurrence. While Psoralen and Ultraviolet A (PUVA) photochemotherapy remains a valuable non-immunosuppressive alternative, regional variations in therapeutic response are not well-characterized in this population. This study aimed to evaluate total and segmental Psoriasis Area and Severity Index (PASI) responses to PUVA in patients with chronic plaque psoriasis and recent internal organ malignancy. Methods: This prospective, single-center, real-world cohort study enrolled 20 adults with moderate-to-severe chronic plaque psoriasis and a recent (p < 0.001). However, regional responses differed significantly: the head and neck improved the most (80.4%), followed by the trunk (72.2%) and upper limbs (72.3%), while the lower limbs showed the weakest response (59.5%; p < 0.001). At baseline, trunk contributed the most to total PASI (38%), while post-treatment, lower-limb lesions accounted for approximately 47% of the remaining total disease burden, showing the highest contribution to total PASI of all body regions. At 6 months, the lower limbs remained the most affected area, with significantly lower improvement (52.9%) compared to other regions. Mean DLQI also improved significantly from 17.2 ± 2.8 to 5.6 ± 2.6 (p < 0.001). Conclusions: PUVA is an effective and safe treatment for patients with psoriasis and a recent history of malignancy. Nevertheless, lower-limb psoriasis is relatively recalcitrant and contributes disproportionately to residual disease burden and relapse. These findings support the use of regional PASI assessment to guide individualized management and clinical expectations in this complex patient group.
- 11 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4525
Open AccessSegmental PASI Evaluation Reveals Reduced PUVA Responsiveness of Lower-Limb Psoriasis in Patients with Internal Organ Malignancy
Background/Objectives: The management of moderate-to-severe psoriasis in patients with a recent history of internal malignancy is a clinical challenge, as systemic immunosuppressive therapies are often avoided because of concerns about cancer recurrence. While Psoralen and Ultraviolet A (PUVA) photochemotherapy remains a valuable non-immunosuppressive alternative, regional variations in therapeutic response are not well-characterized in this population. This study aimed to evaluate total and segmental Psoriasis Area and Severity Index (PASI) responses to PUVA in patients with chronic plaque psoriasis and recent internal organ malignancy. Methods: This prospective, single-center, real-world cohort study enrolled 20 adults with moderate-to-severe chronic plaque psoriasis and a recent (p < 0.001). However, regional responses differed significantly: the head and neck improved the most (80.4%), followed by the trunk (72.2%) and upper limbs (72.3%), while the lower limbs showed the weakest response (59.5%; p < 0.001). At baseline, trunk contributed the most to total PASI (38%), while post-treatment, lower-limb lesions accounted for approximately 47% of the remaining total disease burden, showing the highest contribution to total PASI of all body regions. At 6 months, the lower limbs remained the most affected area, with significantly lower improvement (52.9%) compared to other regions. Mean DLQI also improved significantly from 17.2 ± 2.8 to 5.6 ± 2.6 (p < 0.001). Conclusions: PUVA is an effective and safe treatment for patients with psoriasis and a recent history of malignancy. Nevertheless, lower-limb psoriasis is relatively recalcitrant and contributes disproportionately to residual disease burden and relapse. These findings support the use of regional PASI assessment to guide individualized management and clinical expectations in this complex patient group.
- 4 June 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (11) , 1035-1041
Post‐Streptococcal Neutrophilic Pustular Dermatosis: Expanding the Histopathological Paradigm of Reactive Neutrophilic Dermatoses
Post‐streptococcal pustulosis was first described in 1974 by Tan et al., and was only clearly distinguished from acute generalized exanthematous pustulosis in 1995. It is a rare neutrophilic dermatosis which usually arises following group A streptococcal infections, and is self‐limited in time, typically resolving with 1 month. Clinical presentation includes a roughly symmetrical sterile pustular eruption arising in normal skin, most often affecting acral areas, like palms, soles, and legs. Up to this date, only 26 cases have been documented worldwide, making it a rare phenomenon. Differential diagnosis with other conditions, namely AGEP and pustular psoriasis (PP), might prove challenging. We present a case of a 52‐year‐old woman who came to our clinic with a 2‐day pustular eruption of the acral areas that arose after a streptococcal pharyngitis. A skin biopsy was performed and revealed a dense neutrophilic infiltrate around the superficial dermis with microabscess formation in the dermal papillae, which was consistent with the diagnosis of post‐streptococcal pustulosis. The patient was treated with topical steroids and the lesions resolved within 2 weeks. In this paper, we highlight this rare entity and provide some clinical clues that may help distinguish this disease from AGEP and PP.
- 4 June 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (11) , 1035-1041
Post‐Streptococcal Neutrophilic Pustular Dermatosis: Expanding the Histopathological Paradigm of Reactive Neutrophilic Dermatoses
Post‐streptococcal pustulosis was first described in 1974 by Tan et al., and was only clearly distinguished from acute generalized exanthematous pustulosis in 1995. It is a rare neutrophilic dermatosis which usually arises following group A streptococcal infections, and is self‐limited in time, typically resolving with 1 month. Clinical presentation includes a roughly symmetrical sterile pustular eruption arising in normal skin, most often affecting acral areas, like palms, soles, and legs. Up to this date, only 26 cases have been documented worldwide, making it a rare phenomenon. Differential diagnosis with other conditions, namely AGEP and pustular psoriasis (PP), might prove challenging. We present a case of a 52‐year‐old woman who came to our clinic with a 2‐day pustular eruption of the acral areas that arose after a streptococcal pharyngitis. A skin biopsy was performed and revealed a dense neutrophilic infiltrate around the superficial dermis with microabscess formation in the dermal papillae, which was consistent with the diagnosis of post‐streptococcal pustulosis. The patient was treated with topical steroids and the lesions resolved within 2 weeks. In this paper, we highlight this rare entity and provide some clinical clues that may help distinguish this disease from AGEP and PP.
- Open Access
- 2 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4302
Psoriasis in Obese Patients: Pathophysiological Interactions, Clinical Consequences, and Therapeutic Implications
Background/Objectives: Psoriasis is a chronic immune-mediated inflammatory disease increasingly recognized as a systemic disorder associated with significant metabolic and cardiovascular comorbidities. Among these, obesity (defined as BMI > 30 kg/m2) plays a pivotal role, acting both as a risk factor for psoriasis development and as a modifier of disease severity, clinical phenotype, and therapeutic response. The relationship between psoriasis and obesity is bidirectional and sustained by shared inflammatory and metabolic pathways. This review aims to provide a comprehensive and updated synthesis of the epidemiological association between psoriasis and obesity, to elucidate the underlying pathophysiological mechanisms, and to discuss the clinical and therapeutic implications of excess body weight in psoriasis management. Methods: A narrative review of the literature was conducted, including epidemiological studies, mechanistic research, clinical trials, and real-world evidence addressing the interplay between psoriasis and obesity. Relevant data were identified from peer-reviewed publications focusing on inflammatory pathways, metabolic dysfunction, cardiovascular risk, and treatment outcomes in obese patients with psoriasis. The graphical figures included in this manuscript were created with the assistance of a large language model–based image-generation tool, ChatGPT-5 by OpenAI, using author-defined prompts. The prompts requested schematic medical illustrations summarizing the pathophysiological links between obesity and psoriasis, including adipose tissue dysfunction, adipokine imbalance, systemic inflammation, and activation of the IL-23/Th17 axis. For the therapeutic algorithm, the prompt requested a stepwise clinical flowchart for obese patients with psoriasis, including BMI assessment, comorbidity screening, universal weight-management measures, psoriasis severity stratification, obesity-adapted biologic selection, and management of suboptimal response. The generated images were subsequently reviewed, edited, and approved by the authors to ensure scientific accuracy, clarity, and consistency with the manuscript content. Results: Epidemiological evidence consistently demonstrates a higher prevalence of obesity among patients with psoriasis, with obesity independently associated with increased disease severity. Shared mechanisms include adipose tissue–driven cytokine production, dysregulated adipokine secretion, insulin resistance, endothelial dysfunction, and activation of the IL-23/Th17 axis, collectively contributing to systemic inflammation and accelerated atherogenesis. Obesity negatively impacts the efficacy, pharmacokinetics, and long-term drug survival of conventional systemic agents and biologic therapies, leading to suboptimal clinical outcomes. Conclusions: Obesity is a key determinant of psoriasis burden, influencing disease expression, comorbidities, and therapeutic response. Integrating weight reduction strategies into personalized psoriasis management may improve both dermatological outcomes and overall cardiometabolic health, supporting a holistic approach to patient care.
- 2 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4302
Open AccessPsoriasis in Obese Patients: Pathophysiological Interactions, Clinical Consequences, and Therapeutic Implications
Background/Objectives: Psoriasis is a chronic immune-mediated inflammatory disease increasingly recognized as a systemic disorder associated with significant metabolic and cardiovascular comorbidities. Among these, obesity (defined as BMI > 30 kg/m2) plays a pivotal role, acting both as a risk factor for psoriasis development and as a modifier of disease severity, clinical phenotype, and therapeutic response. The relationship between psoriasis and obesity is bidirectional and sustained by shared inflammatory and metabolic pathways. This review aims to provide a comprehensive and updated synthesis of the epidemiological association between psoriasis and obesity, to elucidate the underlying pathophysiological mechanisms, and to discuss the clinical and therapeutic implications of excess body weight in psoriasis management. Methods: A narrative review of the literature was conducted, including epidemiological studies, mechanistic research, clinical trials, and real-world evidence addressing the interplay between psoriasis and obesity. Relevant data were identified from peer-reviewed publications focusing on inflammatory pathways, metabolic dysfunction, cardiovascular risk, and treatment outcomes in obese patients with psoriasis. The graphical figures included in this manuscript were created with the assistance of a large language model–based image-generation tool, ChatGPT-5 by OpenAI, using author-defined prompts. The prompts requested schematic medical illustrations summarizing the pathophysiological links between obesity and psoriasis, including adipose tissue dysfunction, adipokine imbalance, systemic inflammation, and activation of the IL-23/Th17 axis. For the therapeutic algorithm, the prompt requested a stepwise clinical flowchart for obese patients with psoriasis, including BMI assessment, comorbidity screening, universal weight-management measures, psoriasis severity stratification, obesity-adapted biologic selection, and management of suboptimal response. The generated images were subsequently reviewed, edited, and approved by the authors to ensure scientific accuracy, clarity, and consistency with the manuscript content. Results: Epidemiological evidence consistently demonstrates a higher prevalence of obesity among patients with psoriasis, with obesity independently associated with increased disease severity. Shared mechanisms include adipose tissue–driven cytokine production, dysregulated adipokine secretion, insulin resistance, endothelial dysfunction, and activation of the IL-23/Th17 axis, collectively contributing to systemic inflammation and accelerated atherogenesis. Obesity negatively impacts the efficacy, pharmacokinetics, and long-term drug survival of conventional systemic agents and biologic therapies, leading to suboptimal clinical outcomes. Conclusions: Obesity is a key determinant of psoriasis burden, influencing disease expression, comorbidities, and therapeutic response. Integrating weight reduction strategies into personalized psoriasis management may improve both dermatological outcomes and overall cardiometabolic health, supporting a holistic approach to patient care.
- 3 April 2026
- Published by Elsevier in European Journal of Internal Medicine
- p. 106861
Painful leg nodules, fever, and ankle arthralgia in a middle-aged woman
- 3 April 2026
- Published by Elsevier in European Journal of Internal Medicine
- p. 106861
Painful leg nodules, fever, and ankle arthralgia in a middle-aged woman
- 10 March 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 148, 106826
A woman with fever, feet hypostesia and disseminated papules
- 10 March 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 148, 106826
A woman with fever, feet hypostesia and disseminated papules
- Open Access
- 2 March 2026
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 39 (3) , 237-238
Remembering PLEVA: An Old Disease in Need of Renewed Attention
- 2 March 2026
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 39 (3) , 237-238
Open AccessRemembering PLEVA: An Old Disease in Need of Renewed Attention